Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Lilly and Merck.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer

Release Date: July 31, 2017
Expiration Date: July 31, 2018
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in Chicago in June 2017, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 4 abstracts selected by the program faculty, Ricardo Alvarez, MD, and Sara Hurvitz, MD, as the most clinically relevant from the meeting. For each abstract, a short summary of key clinical data is accompanied by faculty commentary that provides insight into how new data fit into the current field, and how clinicians can apply these findings to their clinical practice to improve patient care. Interactive questions are interspersed throughout the activity to enable engagement, learning, and self-assessment.

CME Activity Table of Contents

  • Abemaciclib Plus Fulvestrant for Patients With Hormone Receptor-Positive, HER2-Negative, Advanced Breast Cancer After Progression on Endocrine Therapy: Results of the Phase III MONARCH 2 Trial
  • Adjuvant Pertuzumab Plus Trastuzumab With Chemotherapy for Early, HER2-Positive Breast Cancer: Results of the APHINITY Trial
  • PARP Inhibition for HER2-Negative, BRCA-Mutated, Metastatic Breast Cancer: Results of the Phase III OlympiAD Trial of Olaparib
  • PD-1 Inhibition With Pembrolizumab for Previously Treated, Metastatic, Triple-Negative Breast Cancer: Results of the Phase II KEYNOTE-086 Trial

Acknowledgment of Commercial Support

This activity is supported by educational grants from Lilly and Merck.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "educational content/audio files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with breast cancer. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Detail the design and endpoints of recent noteworthy clinical trials that evaluated novel strategies for the management of breast cancer
  2. Explain emerging evidence on novel strategies for the treatment of breast cancer
  3. Place into clinical context emerging evidence concerning novel approaches in the care of patients with breast cancer

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.


Faculty, Staff, and Planners' Disclosures

Faculty

Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, OBI Pharma, BioMarin, Cascadian, Seattle Genetics; Other (Paid Travel): Lilly, Novartis, OBI Pharma, Bayer

Ricardo H. Alvarez, MD, MSc
Director, Cancer Research at CTCA- Atlanta
Leader, Breast Cancer Institute CTCA
Clinical Assistant Professor, Augusta University
Augusta GA
Cancer Treatment Centers of America®
Atlanta, GA

Disclosure: Speakers Bureau: Eisai, Inc.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. It is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD, who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on results from the phase III MONARCH 2 trial, an ongoing study evaluating the efficacy of the CDK4/6 inhibitor abemaciclib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who have experienced disease progression after endocrine therapy. During their interviews, Drs. Alvarez and Hurvitz discussed:

  • Their opinions on the clinical significance of the MONARCH 2 results: abemaciclib improved progression-free survival by just over 7 months when added to fulvestrant after 1 line of endocrine therapy.
  • The notable differences in the toxicity profiles of abemaciclib, palbociclib, and ribociclib. Whereas abemaciclib is associated with a lower incidence of grade 3 and 4 neutropenia versus palbociclib and ribociclib, the rates of gastrointestinal toxicity (most notably, diarrhea) are higher with abemaciclib. Additionally, the potential for QT interval prolongation is higher with ribociclib versus the other agents.
  • Factors to consider when selecting a CDK4/6 inhibitor, including their comparative safety profiles, pre-existing comorbidities, and patient preference regarding potential adverse effects and their implications for monitoring (eg, blood count testing, electrocardiogram) and dose schedule.

 




PER Pulse™ Recap (2 of 3)

Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. This is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on results from cohort A of the phase II KEYNOTE-086 trial of pembrolizumab for patients with previously treated metastatic triple-negative breast cancer (TNBC), regardless of PD-L1 expression. In this online activity, the faculty discuss the study results in the context of current and emerging strategies for patients with disease progression after receiving 1 or more lines of therapy for metastatic TNBC.

During their interviews, Drs. Alvarez and Hurvitz discussed:

  • The rationale for, and design of, the KEYNOTE-086 trial, as well as key findings related to cohorts A and B.
  • Their reactions to the cohort A and B data. They noted that it is important to keep in mind that patients in cohort A were heavily pretreated and had a heavy disease burden.
  • The small number of patients with a durable response observed in this trial and the importance of conducting future studies to identify predictive markers.
  • Outcomes based on tumor expression of PD-L1. Survival endpoints were similar regardless of PD-L1 expression.
  • The results of KEYNOTE-086 in the context of previously reported data from studies of checkpoint inhibition for breast cancer.
  • Ongoing investigations of pembrolizumab and other checkpoint inhibitors for breast cancer, including their perspectives on relevant data from the iSPY trial presented in Chicago.

 




PER Pulse™ Recap (3 of 3)

Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. This is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD, who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on results from the phase III OlympiAD trial that compared the efficacy and safety of olaparib versus standard chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. During their interviews, Drs. Alvarez and Hurvitz discussed:

 

  • That an approximately 3-month improvement in progression-free survival was observed with olaparib versus chemotherapy in a population that was heavily pretreated for metastatic germline BRCA-mutated breast cancer (approximately half with triple-negative breast cancer).
  • The promise of these positive data that represent the first phase III clinical trial data in metastatic germline BRCA-mutated breast cancer.
  • The encouraging safety profile of olaparib. The rate of grade 3 or higher adverse effects was 36.6% with olaparib versus 50.5% with chemotherapy. Dr. Hurvitz commented that, overall, it was tolerated quite well and would offer patients a nonchemotherapeutic option if approved.
  • Whether combining a PARP inhibitor with low-dose chemotherapy or an inhibitor of another pathway would augment the positive outcomes observed this study.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By